ssCART-19

ssCART-19 is an investigational autologous cell therapy consisting of anti-CD19 chimeric antigen receptor (CAR)-T cells engineered to express a short hairpin RNA (shRNA) that silences the interleukin-6 (IL-6) gene. This modification aims to reduce the risk and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are significant adverse effects associated with conventional CAR-T therapies. The primary mechanism involves targeting CD19-expressing B-cells, commonly found in B-cell malignancies such as relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Preclinical and clinical studies have demonstrated that ssCART-19 maintains antitumor efficacy while significantly reducing severe CRS and ICANS rates compared to standard CAR-T therapies[1][2][3][4][5][8].

Other names

autologous anti-CD19 Chimeric Antigen Receptors CAR-T cells expressing a short hairpin RNA shRNA against interleukin-6 IL-6